BrainVectis
Developing gene therapy treatments for neurodegenerative diseases by targeting the cholesterol pathway in the brain.
Launch date
Employees
Market cap
-
Enterprise valuation
$4—7m (Dealroom.co estimates Sep 2016.)
Company register number 813073517
Paris Île-de-France (HQ)
Financials
Estimates*
EUR | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|
Revenues | - | - | <1m | 3.8m | 7.5m |
% growth | - | - | - | 181934 % | 96 % |
EBITDA | - | (1.3m) | (1.6m) | <1m | <1m |
% EBITDA margin | - | - | (77009 %) | 9 % | 8 % |
Profit | (<1m) | (<1m) | (<1m) | <1m | 1.2m |
% profit margin | - | - | (46990 %) | 20 % | 17 % |
Recent News about BrainVectis
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.